USPTO serial 98512805
EMPOWER PHARMA
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- VALLILLO, MELISSA C
- Law office
- TMEG LAW OFFICE 105
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EMPOWER PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John A. Yates
John A. Yates Patterson + Sheridan, LLP24 Greenway PlazaSuite 1600Houston, TX 77046Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Supply chain management services for others in the pharmaceutical industry in the field of pharmaceuticals | ACTIVE | — |
| 040 | Contract manufacturing of pharmaceuticals; contract manufacturing of pharmaceutical ingredients, chemical preparations and ingredients for pharmaceuticals, biopharmaceuticals, therapeutic agents, biological and biotechnological preparations, chemical preparations, and reagents for others; contract manufacturing of chemicals, biologics, preparations, and reagents for others in the field of pharmacology, microbiology, toxicology, and biotechnology; commercial production, namely, custom manufacturing of pharmaceuticals | ACTIVE | — |
| 042 | Pharmaceutical drug development services and contract pharmaceutical drug development services; Research and development services of pharmaceutical products and preparations; Research and development services of pharmaceutical products and preparations for others; Conducting research, formulation development, scientific research in the nature of clinical trials and quality assurance for others in the pharmaceutical industry in the field of pharmaceuticals; Conducting post-marketing product support for others in the pharmaceutical industry in the field of pharmaceuticals, namely, post-market surveillance, clinical trials, and studies to further assess the safety, efficacy, or optimal use of approved products; Packaging design services in the pharmaceutical industry in the field of pharmaceuticals; Laboratory research services and contract research services, namely, analytical and microbiological testing for others in the pharmaceutical industry; Laboratory analysis for others in the field of pharmaceuticals; Laboratory research services in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing and analysis of pharmaceuticals per industry standards and for compliance with the requirements of the United States Pharmacopeia regulatory requirements; Quality control testing for others in the pharmaceutical industry; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing of pharmaceutical raw materials to determine conformity with established regulatory standards | ACTIVE | — |
| 045 | Conducting regulatory compliance consulting for others in the pharmaceutical industry in the field of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 22, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Sep 7, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Mar 6, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 6, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 6, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 6, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 6, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 6, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 7, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 5, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 9, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 7, 2024 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Apr 22, 2024 | NWAP | NEW APPLICATION ENTERED | — |